METHODS	Patients were randomized in three groups to receive the following : Group 1-nelfinavir ( 750 mg tid ) , saquinavir soft-gel capsule ( SGC ) ( 800 mg tid ) , and stavudine ( 40 mg bid ) ; Group II-ritonavir ( 400 mg bid ) , saquinavir-SGC ( 400 mg bid ) , and stavudine ( 40 mg bid ) ; or Group III-delavirdine ( 400 mg tid ) , saquinavir-SGC ( 800 mg tid ) , and stavudine ( 40 mg bid ) .\